

## SESSION PROPOSAL 13

### INCREASING DIVERSITY IN CARDIOVASCULAR CLINICAL TRIALS: ENGAGEMENT, RECRUITMENT, LEADERSHIP

Lehana Thabane, Health Research Methods, Evidence, and Impact, McMaster University

#### Description of Session:

Cardiovascular clinical trials inform practice and policy for conditions that have a high disease burden on populations across the world. While the results of these trials are applied broadly, trial participants often do not reflect the diverse patients in whom the results are applied and we rely on anecdotal and observational data to establish the safety and efficacy of treatments in these groups. Diversity is also lacking among clinical trialists, and this appears to be one of several factors associated with the homogeneity of clinical trial participants.

In this 90-minute session that includes patients, cardiovascular researchers, and national society leaders, we will present data on the under-representation of women, the elderly, and those from vast geographic regions in the world as clinical trial participants. We will discuss the impact of this under-representation on clinical care. Similarly, we will present data on the relative gender and geographic homogeneity among clinical trial leaders, with a focus on lead / senior authors of trial publications and trial executive committees. We will discuss factors associated with the underrepresentation of demographic groups as participants and leaders of trials and propose strategies at the clinical trial, institutional, medical society, and academic publishing level that could address these gaps.

This session will engage broad participation via the use of Social Media. Questions from Twitter will be fed into the discussion through the use of a Social Media Ambassador. #ResearchDiversity #SCT20

Chairs: Drs. Lehana Thabane & Mary Noreen Walsh

Social Media Moderators: Dr Araiza Garaygordobil and Ms Ortega

1. Patrick Gee: Engaging patients meaningfully in clinical trials: research participants and partners (10 minutes) 2. Clyde Yancy: Geographic and racial representation in clinical trials: how diverse are we and why does it matter? (12 minutes) 3. Harriette Van Spall: Closing the gender gap in cardiovascular randomized clinical trials: trial recruitment and leadership (12 minutes) 4. Renato Lopes: Can pragmatic trial designs increase diversity among trial participants? (12 minutes) 5. Pamela Douglas: Diversity in cardiovascular research: Do medical societies and journals have a role? (12 minutes)

Discussion: 30 Minutes

#### Contributors:

Patrick Gee , Co-founder iAdvocate

Clyde Yancy, Northwestern University

Harriette Van Spall , McMaster University

Renato Lopes , Duke University

Pamela S. Douglas, Duke University

Diego Araiza Garaygordobil , National Institute of Cardiology of México

Rebecca Ortega, Women As One

Mary Noreen Walsh , Indiana University School of Medicine